ScholarIQanswers from OpenAlex & ORCID
Maura L. Gillison
ResearcherPublications, citations & collaboration network
Maura L. Gillison is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Maura L. Gillison have?
ScholarIQindexed works
Maura L. Gillison has 625 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Maura L. Gillison have?
ScholarIQcitation count
Maura L. Gillison has 60,473 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Maura L. Gillison?
ScholarIQh-index
Maura L. Gillison has an h-index of 98 in OpenAlex.
What is the i10-index of Maura L. Gillison?
ScholarIQi10-index
Maura L. Gillison has an i10-index of 225 in OpenAlex.
What is the ORCID of Maura L. Gillison?
ScholarIQorcid
The ORCID for Maura L. Gillison is on the source record.
What is the OpenAlex record for Maura L. Gillison?
ScholarIQopenalex
The OpenAlex for Maura L. Gillison is on the source record.
What are the most-cited papers on Maura L. Gillison?
ScholarIQmost cited works
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang, Jonathan Harris, Richard Wheeler, Randal S. Weber, David I. Rosenthal, Phuc Félix Nguyen‐Tan, William H. Westra, Christine H. Chung, Richard C. Jordan, Charles Lu, Harold Kim, Rita Axelrod, C. Craig Silverman, Kevin P. Redmond, Maura L. Gillison
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Mark Lynch, Vijayvel Jayaprakash, Li Li, Maura L. Gillison
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
Yanshuo Chu, Enyu Dai, Yating Li, Guangchun Han, Guangsheng Pei, Davis R. Ingram, Krupa Thakkar, Jiang‐Jiang Qin, Minghao Dang, Xiuning Le, Can Hu, Qing Deng, Ansam Sinjab, Pravesh Gupta, Ruiping Wang, Dapeng Hao, Fuduan Peng, Xinmiao Yan, Yunhe Liu, Shumei Song, Shaojun Zhang, John V. Heymach, Alexandre Reuben, Yasir Y. Elamin, Melissa Pool Pizzi, Yang Lü, Rossana Lazcano, Jian Hu, Mingyao Li, Michael A. Curran, P. Andrew Futreal, Anirban Maitra, Amir A. Jazaeri, Jaffer A. Ajani, Charles Swanton, Xiangdong Cheng, Hussein A. Abbas, Maura L. Gillison, Krishna Bhat, Alexander J. Lazar, Michael R. Green, Kevin Litchfield, Humam Kadara, Cassian Yee, Linghua Wang
Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity
Phuc Félix Nguyen‐Tan, Qiang Zhang, K. Kian Ang, Randal S. Weber, David I. Rosenthal, Denis Soulières, Harold Kim, Craig Silverman, Adam Raben, Thomas J. Galloway, A. Fortin, Elizabeth Gore, William H. Westra, Christine H. Chung, Richard C. Jordan, Maura L. Gillison, Marcie List, Quynh‐Thu Le